Article Text

Download PDFPDF
Journal club
Triple therapy for idiopathic pulmonary fibrosis
  1. Mark G Jones
  1. Correspondence to Dr Mark G Jones, Department of Respiratory Medicine, University Hospital Southampton NHS Foundation Trust, Southampton General Hospital, Mailpoint 255, Southampton SO16 6YD, UK; mark.jones{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

This multicentre, randomised, double-blind placebo-controlled trial was designed to address the effectiveness of the antioxidant, N-Acetylcysteine (NAC), alone and in ‘triple’ therapy (prednisolone, azathioprine and NAC) in idiopathic pulmonary fibrosis (IPF). Patients with IPF and mild to moderate lung function impairment (FVC≥50% and TLCO≥30%) were assigned to receive triple therapy, NAC alone or matched placebo …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.